top of page
  • Writer's pictureKiran Dhillon

Seattle Met Magazine features CVI HER2 ICD DNA vaccine for breast cancer


Seattle Met Magazine recently interviewed CVI Director, Dr. Nora Disis, and CVI Director of Clinical Trials, Dr. Shaveta Vinayak on our recent publication in JAMA Oncology of our Phase I clinical trial with our HER2 ICD DNA vaccine tested in individuals with HER2+ advanced-stage breast cancer. The study showed that the vaccines are safe (very few side effects) and 75-85% of patients (depending on dose) with advanced stage breast cancer were alive 10 years after vaccination. This vaccine is now in a multinational randomized Phase II clinical trial for breast cancer.










コメント


Post: Blog2_Post
bottom of page